CEO
Dennis Carlo
Employees
17
Industry
Pharmaceutical Preparation Manufacturing
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Loading...
Open
0.75
Mkt cap
7.3M
Volume
119K
High
0.79
P/E Ratio
-0.08
52-wk high
21.70
Low
0.75
Div yield
N/A
52-wk low
0.45
Portfolio Pulse from Happy Mohamed
September 07, 2023 | 4:02 pm
Portfolio Pulse from Benzinga Insights
September 05, 2023 | 5:34 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2023 | 1:19 pm
Portfolio Pulse from Benzinga Insights
August 09, 2023 | 4:27 pm
Portfolio Pulse from Benzinga Newsdesk
August 04, 2023 | 2:18 pm
Portfolio Pulse from Lisa Levin
August 04, 2023 | 1:56 pm
Portfolio Pulse from Lisa Levin
August 04, 2023 | 1:33 pm
Portfolio Pulse from Benzinga Insights
August 04, 2023 | 1:25 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.